Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Strizki · SciRah

Researcher profile · Semantic Scholar

J. Strizki

Share profile

J. Strizki — researcher profile on SciRah

h-index: 28
Works: 61
Citations: 4,985

Most-cited papers

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, M. Gomes da Silva, D. Musungaie, E. Kovalchuk +18 more
2021New England Journal of Medicine1,512 citations Open access
Semantic Scholar
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
A. Trkola, S. Kuhmann, J. Strizki, Elizabeth Maxwell +13 more
2002Proceedings of the National Academy of Sciences of the United States of America335 citations Open access
Semantic Scholar
SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo
J. Strizki, Serena Xu, Nicole E. Wagner, Lisa Wojcik +21 more
2001Proceedings of the National Academy of Sciences of the United States of America316 citations Open access
Semantic Scholar
CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons.
E. Lavi, J. Strizki, A. M. Ulrich, W. Zhang +5 more
1997American Journal of Pathology261 citations
Semantic Scholar
Discovery and Characterization of Vicriviroc (SCH 417690), a CCR5 Antagonist with Potent Activity against Human Immunodeficiency Virus Type 1
J. Strizki, C. Tremblay, Serena Xu, Lisa Wojcik +14 more
2005Antimicrobial Agents and Chemotherapy217 citations Open access
Semantic Scholar
Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor
S. Kuhmann, P. Pugach, K. Kunstman, Joann M. Taylor +9 more
2004Journal of Virology215 citations Open access
Semantic Scholar
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
A. Limaye, Klemens Budde, A. Humar, F. Vincenti +8 more
2023Journal of the American Medical Association (JAMA)189 citations Open access
Semantic Scholar
Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
A. Marozsan, S. Kuhmann, T. Morgan, C. Herrera +5 more
2005Virology171 citations Open access
Semantic Scholar
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonis
J. Tagat, S. Mccombie, D. Nazareno, M. Labroli +8 more
2004Journal of Medicinal Chemistry140 citations Open access
Semantic Scholar
Chemokine Receptor Utilization by Human Immunodeficiency Virus Type 1 Isolates That Replicate in Microglia
J. Shieh, Andrew V. Albright, M. Sharron, S. Gartner +3 more
1998Journal of Virology133 citations Open access
Semantic Scholar
Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5.
M. Vierboom, P. Zavodny, Chuan-Chu Chou, J. Tagat +9 more
2005Arthritis & Rheumatism106 citations
Semantic Scholar
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.
J. Arribas, S. Bhagani, S. Lobo, I. Khaertynova +16 more
2021NEJM Evidence101 citations
Semantic Scholar
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
R. Ogert, Lisa Wojcik, Catherine A. Buontempo, Lei Ba +4 more
2008Virology98 citations Open access
Semantic Scholar
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist.
J. Tagat, R. Steensma, S. Mccombie, Dennis V. Nazareno +9 more
2001Journal of Medicinal Chemistry94 citations Open access
Semantic Scholar
Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.
A. Palani, Sherry Shapiro, John W. Clader, W. Greenlee +4 more
2001Journal of Medicinal Chemistry88 citations Open access
Semantic Scholar
A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1(89.6) but not the T-tropic isolate HIV-1(HxB)
J. Strizki, J. D. Turner, R. Collman, J. Hoxie +1 more
1997Journal of Virology78 citations Open access
Semantic Scholar
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults.
Y. Caraco, G. Crofoot, P. Moncada, A. Galustyan +15 more
2021NEJM Evidence75 citations
Semantic Scholar
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.
C. Douglas, Richard J. O. Barnard, D. Holder, R. Leavitt +9 more
2019Journal of Infectious Diseases74 citations Open access
Semantic Scholar
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies.
R. Barnard, J. Howe, R. Ogert, S. Zeuzem +14 more
2013Virology74 citations Open access
Semantic Scholar
Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.
A. Palani, Sherry Shapiro, H. Josien, T. Bara +5 more
2002Journal of Medicinal Chemistry72 citations Open access
Semantic Scholar
HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.
Guo-Xin Wu, M. Swanson, A. Talla, Donald J. Graham +13 more
2017JCI Insight67 citations Open access
Semantic Scholar
Differential host-dependent expression of alpha-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model.
P. Repik, J. Strizki, U. Galili
1994Journal of General Virology59 citations
Semantic Scholar
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.
S. Mccombie, J. Tagat, S. Vice, Sue-Ing Lin +9 more
2003Bioorganic & Medicinal Chemistry Letters44 citations Open access
Semantic Scholar
Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types
Thomas J. Ketas, P. Klasse, C. Spenlehauer, M. Nesin +6 more
2003AIDS Research and Human Retroviruses42 citations
Semantic Scholar
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
Matthew G. Johnson, J. Strizki, Michelle L. Brown, H. Wan +13 more
2023Infection37 citations Open access
Semantic Scholar
Placental Production of Immunoregulatory Factors: Trophoblast is a Source of Interleukin-1
E. Main, J. Strizki, Peter Schochet
198734 citations
Semantic Scholar
Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides.
A. Palani, Sherry Shapiro, J. Clader, W. Greenlee +5 more
2003Bioorganic & Medicinal Chemistry Letters31 citations Open access
Semantic Scholar
Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings
C. Hoesley, Beatrice A. Chen, P. Anderson, C. Dezzutti +11 more
2018Clinical Infectious Diseases28 citations Open access
Semantic Scholar
Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial.
P. McNicholas, Yi Wei, J. Whitcomb, W. Greaves +3 more
2010Journal of Infectious Diseases28 citations
Semantic Scholar
Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of SVR in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis.
M. Rodríguez-Torres, A. Stoehr, E. Gane, L. Serfaty +9 more
2014Clinical Gastroenterology and Hepatology27 citations
Semantic Scholar
Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1)
P. McNicholas, P. Mann, Lisa Wojcik, P. Qiu +5 more
2011Journal of Acquired Immune Deficiency Syndromes26 citations Open access
Semantic Scholar
Biological evaluation and interconversion studies of rotamers of SCH 351125, an orally bioavailable CCR5 antagonist.
A. Palani, Sherry Shapiro, J. Clader, W. Greenlee +6 more
2003Bioorganic & Medicinal Chemistry Letters26 citations Open access
Semantic Scholar
Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis.
R. Barnard, Carolyn M. McHale, W. Newhard, C. Cheney +10 more
2013Virology20 citations Open access
Semantic Scholar
Application of affinity selection-mass spectrometry assays to purification and affinity-based screening of the chemokine receptor CXCR4.
Charles E. Whitehurst, Zhiping Yao, Denise Murphy, Mingxuan Zhang +9 more
2012Combinatorial chemistry & high throughput screening20 citations
Semantic Scholar
Phase 1 Pharmacokinetic Trial of 2 Intravaginal Rings Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048
Albert Y. Liu, Jing-Yang Zhang, P. Anderson, Theresa Wagner +8 more
2018Clinical Infectious Diseases19 citations Open access
Semantic Scholar
Three new compounds from the plant Lippia alva as inhibitors of chemokine receptor 5 (CCR5).
V. Hegde, Haiyan Pu, Mahesh G. Patel, P. Das +5 more
2004Bioorganic & Medicinal Chemistry Letters18 citations Open access
Semantic Scholar
A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027
J. Bauermeister, J. Golinkoff, A. Carballo-Diéguez, Rebecca Giguere +14 more
2019Aids and Behavior14 citations Open access
Semantic Scholar
543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
J. Grobler, J. Strizki, N. Murgolo, Wei Gao +8 more
2021Open Forum Infectious Diseases12 citations Open access
Semantic Scholar
Targeting HIV attachment and entry for therapy.
J. Strizki
2008Advances in Pharmacology11 citations
Semantic Scholar
Structural protein relationships among eastern equine encephalitis viruses.
J. Strizki, P. Repik
1994Journal of General Virology11 citations Open access
Semantic Scholar
Development and Evaluation of Nanoparticles-in-Film Technology to Achieve Extended In Vivo Exposure of MK-2048 for HIV Prevention
X. Tong, S. K. Patel, Jing Li, D. Patton +7 more
2022Polymers9 citations Open access
Semantic Scholar
A Phase I study to explore the activity and safety of SCH532706, a small molecule chemokine receptor-5 antagonist in HIV type-1-infected patients
S. Pett, M. McCarthy, D. Cooper, K. Macrae +5 more
2009Antiviral Therapy9 citations Open access
Semantic Scholar
Developing and applying ultrasensitive p24 protein immunoassay for HIV latency
B. Howell, G. Wu, M. Swanson, Meiqing Lu +6 more
20156 citations Open access
Semantic Scholar
Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
P. McNicholas, R. Vilchez, W. Greaves, Sushma Kumar +3 more
2012Journal of Clinical Virology6 citations
Semantic Scholar
1208 EVALUATION OF NS3 AMINO ACID VARIANTS IN A PHASE 1B STUDY OF GENOTYPE 1 (GT1) AND GT3 INFECTED PATIENTS WITH THE HCV PROTEASE INHIBITOR, MK-5172
J. Strizki, R. Barnard, C. Cheney, Carolyn M. McHale +6 more
20126 citations
Semantic Scholar
Use of primary CNS cultures to investigate HIV neurotropism.
F. Gonźalez-Scarano, J. Strizki, Andrew V. Albright, J. Shieh
1997Journal of Neurovirology6 citations
Semantic Scholar
Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.
P. Buontempo, Lisa Wojcik, Catherine A. Buontempo, R. Ogert +3 more
2009Virology5 citations Open access
Semantic Scholar
Vicriviroc Is a Novel, Potent CCR5 Inhibitor With Outstanding Pharmaceutic, Pharmacokinetic and PharmaCodynamic (PK/PD) Properties
L. Dunkle, A. Keung, A. Sansone, J. Strizki
2005Retrovirology4 citations Open access
Semantic Scholar
153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
J. Strizki, N. Murgolo, John M. Gaspar, J. Howe +5 more
2022Open Forum Infectious Diseases3 citations Open access
Semantic Scholar
CXCR-4. a Co-Receptor for HIV-I. is Expressed in the Human Brain in a Variety of Cell Types Including Neurons and Microglia
E. Lavi, J. Strizki, A. M. Ulrich, W. Zhane +5 more
19973 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

B. Baroudy×10
Invite
B. Baroudy — researcher profile on SciRah
K. Cox×9
Invite
K. Cox — researcher profile on SciRah
Lisa Wojcik×8
Invite
Lisa Wojcik — researcher profile on SciRah
J. Tagat×7
Invite
J. Tagat — researcher profile on SciRah

×7

Invite

A. Palani — researcher profile on SciRah

Invite

S. Mccombie — researcher profile on SciRah

Invite

D. Hazuda — researcher profile on SciRah

Invite

J. Grobler — researcher profile on SciRah

Sherry Shapiro×6

Invite

Sherry Shapiro — researcher profile on SciRah

Invite

Serena Xu — researcher profile on SciRah

Invite

J. Clader — researcher profile on SciRah

Invite

J. Moore — researcher profile on SciRah